Indoco Remedies · NSE: INDOCO · BSE: 532612
Q3 FY26 results · Oct–Dec 2025
Indoco Remedies reported revenue from operations of ₹445.36 crore (up 8.5% from Q3 FY25) and net loss of ₹29.45 crore for Q3 FY26 (Oct–Dec 2025), on a consolidated basis.
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 445.36 | 410.55 | +8.5% | 484.67 | −8.1% |
| Other income | 0.98 | 0.85 | +15.3% | 0.76 | +28.9% |
| Total income | 446.34 | 411.40 | +8.5% | 485.43 | −8.1% |
| Profit before tax | (31.31) | (30.96) | Loss widened | (13.53) | Loss widened |
| Net profit for the period | (29.45) | (28.40) | Loss widened | (9.21) | Loss widened |
| Attributable to shareholders of the company | (29.79) | (26.39) | Loss widened | (7.93) | Loss widened |
| EPS, basic (₹) | (3.20) | (3.08) | Loss widened | (1.00) | Loss widened |
| Net margin (%) | -6.6 | -6.9 | -1.9 |
| Item | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 400.51 | 372.98 | +7.4% | 442.12 | −9.4% |
| Other income | 7.17 | 4.26 | +68.3% | 6.54 | +9.6% |
| Total income | 407.68 | 377.24 | +8.1% | 448.66 | −9.1% |
| Profit before tax | (20.45) | (13.36) | Loss widened | 9.76 | Turned loss |
| Net profit for the period | (20.00) | (10.23) | Loss widened | 15.05 | Turned loss |
| EPS, basic (₹) | (2.17) | (1.11) | Loss widened | 1.63 | Turned loss |
| Net margin (%) | -5.0 | -2.7 | 3.4 |
Consolidated
- Filed with BSE
- 03 Feb 2026, 16:55 IST
- Board meeting
- 03 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 03 Feb 2026, 16:55 IST
- Board meeting
- 03 Feb 2026
- Period
- 01 Oct 2025 to 31 Dec 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE